Nancy Harrison is cofounder and the previous president of MSI Methylation Sciences, a private venture-backed development company with a novel treatment of depression in Phase II development. Currently, she is a consultant to several companies, acts as the chair of the board for Lifesciences BC, and a board member of Genome BC I2 Fund, CDRD, Industrial Research Assistance Program (IRAP), and the Polygon Gallery. She is a former partner and senior vice president of Ventures West Management Inc. During her tenure with Ventures West, the life sciences portfolio grew from 0% of the overall investment portfolio to approximately 30% of investments. The firm grew from about $90 million under management to about $750 million under management in eight historical funds. Nancy participated in more than 30 investments over her time at the firm and specialized in helping Canadian life sciences companies raise Series B rounds through accessing US venture capital funds. Some of these investments include companies such as Angiotech Pharmaceuticals, AnorMed, Caprion Pharmaceuticals, Celator Technologies, Alder Biopharmaceuticals, Xenon Pharmaceuticals, Salmedix, Sembiosys Genetics, and many other biotechnology firms. She has won The Caldwell Partners 40 under 40 Award for outstanding young business professionals and the Business in Vancouver’s top 40 under 40 award for young entrepreneurs, professionals, and executives. She holds an MBA from McGill University and a BSc in Geophysical Engineering from Queen’s University.